Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director · President and CEO | October 01, 2026 | October 05, 2026 |
| VERACYTE, INC.VCYT · Entity 2018 | Chief Commercial Officer | December 02, 2020 | December 04, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 644,937 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 8,511 · Balance 644,937 F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
VERACYTE, INC.
Report date December 02, 2020 · Filed December 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,844 |
Reported balance
After 2020-12-02 transaction · row 1
1 source rowRow 1 · 2020-12-02 · Tax withholding · Disposed 465 · Balance 73,844 F1: The reporting person is reporting the withholding of 217 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 437 and 500 Restricted Stock Units, respectively, granted on March 2, 2018 and February 28, 2019, respectively and does not represent a sale by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is reporting the withholding of 217 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 437 and 500 Restricted Stock Units, respectively, granted on March 2, 2018 and February 28, 2019, respectively and does not represent a sale by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 22, 2019 Filed Oct 24, 2019 22:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 15,791 | $27.50 | $434,320.40 |
DisclosureSEC source: 0001384101-19-000134 · wf-form4_157195688905784.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,792 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $27.00 to $27.99. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 22:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 16,091 | $6.45 | $103,786.95 |
DisclosureSEC source: 0001384101-19-000134 · wf-form4_157195688905784.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:50 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 18,593 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000124 · wf-form4_156875340783665.xml · derivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,907 Underlying: Common Stock · 18,593 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:50 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 18,593 | $25.66 | $477,088.94 |
DisclosureSEC source: 0001384101-19-000124 · wf-form4_156875340783665.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.21 to $26.04. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:50 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 18,593 | $5.98 | $111,186.14 |
DisclosureSEC source: 0001384101-19-000124 · wf-form4_156875340783665.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 152 | $25.09 | $3,813.68 |
DisclosureSEC source: 0001384101-19-000116 · wf-form4_156771844700157.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 F1 · shares: The reporting person is reporting the withholding of 152 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 438 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. F2 · balance_after: Includes 287 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.